Domestic substitution and expanding domestic demand, in essence, is not the corresponding technology and big consumption? The direction has been given to everyone above, so you can just wait for the trend to make money.But it didn't go up yesterday, but it went up today. Why?Second, you must have the patience to hold shares. I told you in early trading that the market in December may be difficult as a whole, not to say that the index risk is great. Under the tone of stabilizing the stock market, there will be no big risk as a whole, but it is uncomfortable for those with high speculation.
Although many people are still pessimistic, I am confident that the trend is bullish. Ups and downs will make many people lose money. Everyone will never make money outside their own cognition. It is better to wait patiently in the direction of their own cognition.(2) Second, the appreciation of RMB exchange rate is obvious today. Yesterday's trend made everyone dissatisfied, but yesterday's exchange rate performance was very firm. Some people say that the exchange rate strength has anything to do with investors?(1) First, there was an obvious shrinkage in the opening today. My understanding is that I bought what I should have bought yesterday and sold what I should have sold yesterday. Today, the market has risen, and everyone will not be so impulsive. Therefore, the main funds in the venue are self-directed.
At this time, institutions will either choose some high dividends or some oversold industry leaders as a defense. Those who want to catch the daily limit and buy and sell in day trading are more likely to lose money.Today, it is actually very consistent with the characteristics of institutional efforts, because chasing up and down is the characteristic of many retail investors, but institutions generally regard retail investors as their own opponents.The plates were those that opened higher yesterday, and they have been further repaired today. At the end of the year, don't always think about chasing the daily limit, low-level consumer medicine, and the industry's low valuation leader, holding it steadily in the cyclical direction.
Strategy guide 12-14
Strategy guide